Results 21 to 30 of about 485 (131)

A novel shark VNAR antibody-based immunotoxin targeting TROP-2 for cancer therapy [PDF]

Acta Pharmaceutica Sinica B
TROP-2, a tumor-associated antigen, has been implicated in the progression of various epithelial tumors. Due to its favorable expression profile, TROP-2 has emerged as a promising target for antibody-drug conjugates (ADCs) based anti-tumor therapies. Although ADCs have shown efficacy in cancer treatment, their application in solid tumors is hindered by
Yanqing Wang, Zhicheng Zuo, Qiang Wang   +2 more
exaly   +4 more sources

First pan-specific vNAR against human TGF-β as a potential therapeutic application: in silico modeling assessment [PDF]

Scientific Reports, 2023
Immunotherapies based on antibody fragments have been developed and applied to human diseases, describing novel antibody formats. The vNAR domains have a potential therapeutic use related to their unique properties.
Mirna Burciaga-Flores, Ana Laura Márquez-Aguirre, Salvador Dueñas, Jahaziel Gasperin-Bulbarela, Alexei F. Licea-Navarro, Tanya A. Camacho-Villegas   +5 more
doaj   +2 more sources

Theranostic vNAR-Based Immunoconjugates Achieve Selective Intracellular Cisplatin Delivery in Embedded 3D HER2-Positive Breast Cancer In Vitro Model [PDF]

Pharmaceuticals
Background/Objectives: Precise intracellular delivery of chemotherapeutics remains a major challenge in HER2-positive breast cancer, where intratumoral heterogeneity and limited tissue penetration constrain efficacy.
Andrea C. Alfonseca-Ladrón de Guevara, Alejandro Manzanares-Guzmán, Jessica A. Badillo-Mata, Mirna Burciaga-Flores, Pavel H. Lugo-Fabres, Tanya A. Camacho-Villegas   +5 more
doaj   +2 more sources

Isolation and Characterization of Targeting-HBsAg VNAR Single Domain Antibodies from Whitespotted Bamboo Sharks (Chiloscyllium plagiosum) [PDF]

Marine Drugs, 2023
Immunoglobulin new antigen receptor (IgNAR) is a naturally occurring antibody that consists of only two heavy chains with two independent variable domains.
Xierui Jiang, Shan Sun, Zengpeng Li, Mingliang Chen   +3 more
doaj   +2 more sources

Brain delivery of biologics using a cross‐species reactive transferrin receptor 1 VNAR shuttle [PDF]

The FASEB Journal, Volume 34, Issue 10, Page 13272-13283, October 2020., 2020
Abstract Transferrin receptor 1 (TfR1) mediated transcytosis is an attractive strategy to enhance brain uptake of protein drugs, but translation remains a challenge. Here, a single domain shark antibody VNAR fragment (TXB2) with similar affinity to murine and human TfR1 was used to shuttle protein cargo into the brain. TXB2 was fused to a human IgG1 Fc
Dag Sehlin, Pawel Stocki, Tobias Gustavsson, Greta Hultqvist, Frank S. Walsh, J. Lynn Rutkowski, Stina Syvänen   +6 more
wiley   +4 more sources

A Single-Domain VNAR Nanobody Binds with High-Affinity and Selectivity to the Heparin Pentasaccharide Fondaparinux [PDF]

International Journal of Molecular Sciences
Glycosaminoglycans (GAGs) are key ligands for proteins involved in physiological and pathological processes. Specific GAG-binding patterns are rarely identified, with the heparin pentasaccharide as an Antithrombin-III ligand being the best characterized.
Gschwandtner M, Derler R, Talker E, Trojacher C, Gubensäk N, Becker W, Gerlza T, Klaus Z, Stocki P, Walsh FS, Rutkowski JL, Kungl A.   +11 more
exaly   +4 more sources

Identification and characterization of shark VNARs targeting the Helicobacter pylori adhesin HpaA

Artificial Cells, Nanomedicine, and Biotechnology, 2023
Helicobacter pylori (H. pylori) is recognized as a pathogen associated with several gastrointestinal diseases. The current treatments exhibit numerous drawbacks, including antibiotic resistance. H.
Yanchun Gao, Ruihong Wang, Lin Liu, Shitao Feng, Xiaozhi Xi, Wengong Yu, Yuchao Gu, Ye Wang   +7 more
doaj   +3 more sources

Shark IgNAR: The Next Broad Application Antibody in Clinical Diagnoses and Tumor Therapies? [PDF]

Marine Drugs, 2023
Antibodies represent a relatively mature detection means and serve as therapeutic drug carriers in the clinical diagnosis and treatment of cancer—among which monoclonal antibodies (mAbs) currently occupy a dominant position.
Xiaofeng Jiang, Ling Sun, Chengwu Hu, Feijian Zheng, Zhengbing Lyu, Jianzhong Shao   +5 more
doaj   +2 more sources

Generation of shark single-domain antibodies as an aid for Cryo-EM structure determination of membrane proteins: Use hyaluronan synthase as an example [PDF]

Journal of Structural Biology: X
In cartilaginous fish, the immunoglobulin new antigen receptor (IgNAR) is naturally devoid of light chains. The variable regions of IgNAR (VNARs) are solely responsible for antigen recognition, similar to VHHs (variable domain of the heavy chain of heavy-
Penghui Deng, Xiaoyue Zhang, Jianqing Wen, Mingce Xu, Pengwei Li, Hao Wang, Yunchen Bi   +6 more
doaj   +2 more sources

Identification of Anti-TNFα VNAR Single Domain Antibodies from Whitespotted Bambooshark (Chiloscyllium plagiosum)

Marine Drugs, 2022
Tumor necrosis factor α (TNFα), an important clinical testing factor and drug target, can trigger serious autoimmune diseases and inflammation. Thus, the TNFα antibodies have great potential application in diagnostics and therapy fields.
Linfei Zhao, Mingliang Chen, Xiaona Wang, Shoukai Kang, Weiwei Xue, Zengpeng Li   +5 more
doaj   +3 more sources